ARCH Venture Partners, founded in 1986 and based in Chicago, Illinois, is a venture capital firm that specializes in investing in early-stage technology companies, particularly in the life sciences sector. The firm focuses on innovations that emerge from academic research institutions and national laboratories, making it a recognized leader in the commercialization of such technologies. ARCH invests conservatively in seed rounds to mitigate risk and subsequently leads or co-leads further financing rounds, aiming for a seat on the Board of Directors. Its investment strategy encompasses a wide range of sectors, including biotechnology, pharmaceuticals, advanced materials, and clean technology, among others. ARCH primarily invests in the United States while also targeting opportunities in countries like Canada, Ireland, South Korea, China, and Japan. The firm has raised over $3 billion across ten venture funds and has supported more than 150 companies in their early capital rounds.
5001 Plaza on the Lake Blvd., Suite 103 Austin, TX 78746
Jacob Bauer
Venture Partner
Kristina Burow
Managing Director
Clinton Bybee
Co-Founder and Managing Director
Keith Crandell
Founder and Managing Director
David Cruikshank
Partner
Kaye Foster
Venture Partner
Joseph Jeong
Venture Partner
George Kadifa
Venture Partner
Sean Kendall
Partner
Jay Kocherlakota
Senior Associate
Jonathan Lim
Venture Partner
Peter Mintun Ph.D
Associate
Carol Suh
Partner
Paul Thurk
Managing Director Europe
George Scangos Ph.D
Venture Partner
Past deals in Wellness
Metsera
Seed Round in 2024
Metsera is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for obesity and metabolic conditions. The company focuses on advancing a variety of oral and injectable treatment options, including incretin, non-incretin, and combination therapies. These treatments are designed to address multiple therapeutic targets, positioning Metsera to meet the evolving demands of the weight loss treatment landscape. Additionally, Metsera integrates proprietary health technology tools to provide personalized care, enhancing the effectiveness of its therapeutic offerings.
Metsera
Series A in 2024
Metsera is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for obesity and metabolic conditions. The company focuses on advancing a variety of oral and injectable treatment options, including incretin, non-incretin, and combination therapies. These treatments are designed to address multiple therapeutic targets, positioning Metsera to meet the evolving demands of the weight loss treatment landscape. Additionally, Metsera integrates proprietary health technology tools to provide personalized care, enhancing the effectiveness of its therapeutic offerings.
Accompany Health
Series A in 2024
Accompany Health is a health technology platform that delivers comprehensive in-home care to patients, particularly in underserved regions. The company focuses on providing primary care services, including chronic illness management and treatment of new symptoms. It aims to support low-income patients with complex health needs throughout their care journeys, offering both at-home and virtual services. By fostering long-term relationships with patients, Accompany Health ensures that individuals receive continuous support, with access to care available at all hours. This approach eliminates the need for waiting rooms and enhances the overall patient experience by emphasizing dignity and accessibility in healthcare.
Recuro Health
Series B in 2023
Recuro Health is a developer of an integrated digital health platform that aims to transform the U.S. healthcare system from a reactive, disease-focused model to one centered on population health and outcomes. The company provides a tailored Digital Medical Home that caters to specific healthcare needs, offering essential virtual care services, including primary care, behavioral health, and urgent care. By equipping employers, providers, and managed care organizations with various digital tools, education, and guidance, Recuro Health enables patients to actively engage in their healthcare through health assessments and interactive communication with professionals, whether via messaging or video. This approach seeks to enhance patient involvement and improve health outcomes across diverse settings.
Homeward
Series B in 2022
Homeward is rearchitecting rural health and care for the 60 million Americans living in rural communities. Homeward employs a multidisciplinary care team, available both virtually and on the ground via mobile care units, with in-home remote monitoring to better connect patients to high-quality, affordable, and comprehensive care. Today, the company partners with Medicare Advantage plans, taking on the full risk of their members to improve outcomes and reduce costs.
Recuro Health
Convertible Note in 2022
Recuro Health is a developer of an integrated digital health platform that aims to transform the U.S. healthcare system from a reactive, disease-focused model to one centered on population health and outcomes. The company provides a tailored Digital Medical Home that caters to specific healthcare needs, offering essential virtual care services, including primary care, behavioral health, and urgent care. By equipping employers, providers, and managed care organizations with various digital tools, education, and guidance, Recuro Health enables patients to actively engage in their healthcare through health assessments and interactive communication with professionals, whether via messaging or video. This approach seeks to enhance patient involvement and improve health outcomes across diverse settings.
Feelmore Labs
Debt Financing in 2022
Feelmore Labs is a health and wellness technology company based in New York City, specializing in the development of non-invasive wearable devices that aim to enhance emotional well-being. By focusing on the modulation of the insula, a deep brain region responsible for emotional responses, Feelmore Labs' devices help users achieve a sense of calm, reduce stress and anxiety, and improve sleep patterns. This innovative approach positions the company at the forefront of a new category of medical and consumer devices designed to positively impact individuals' lives.
Recuro Health
Series A in 2021
Recuro Health is a developer of an integrated digital health platform that aims to transform the U.S. healthcare system from a reactive, disease-focused model to one centered on population health and outcomes. The company provides a tailored Digital Medical Home that caters to specific healthcare needs, offering essential virtual care services, including primary care, behavioral health, and urgent care. By equipping employers, providers, and managed care organizations with various digital tools, education, and guidance, Recuro Health enables patients to actively engage in their healthcare through health assessments and interactive communication with professionals, whether via messaging or video. This approach seeks to enhance patient involvement and improve health outcomes across diverse settings.
Feelmore Labs
Series B in 2019
Feelmore Labs is a health and wellness technology company based in New York City, specializing in the development of non-invasive wearable devices that aim to enhance emotional well-being. By focusing on the modulation of the insula, a deep brain region responsible for emotional responses, Feelmore Labs' devices help users achieve a sense of calm, reduce stress and anxiety, and improve sleep patterns. This innovative approach positions the company at the forefront of a new category of medical and consumer devices designed to positively impact individuals' lives.
LunaPBC
Venture Round in 2019
LunaPBC, Inc. is a Public Benefit Corporation based in San Diego, California, that develops a community-owned platform for genomic and medical research. The company's primary offering, LunaDNA, serves as a knowledge database where individuals can share their health and DNA data to contribute to health research and drive medical discoveries. This platform is designed to benefit both non-profit and for-profit health research projects, facilitating collaboration among pharmaceutical, insurance, and healthcare IT companies. In addition to advancing medical research, LunaPBC allows its members to share in the financial benefits derived from medical breakthroughs, promoting a model of shared community ownership.
Arivale
Series B in 2015
Arivale Inc. is a wellness service provider that focuses on helping individuals optimize their health and prevent disease through a scientific approach. Founded in 2014 and headquartered in Seattle, Washington, the company analyzes various aspects of individual health, including genetics, blood markers, the gut microbiome, and lifestyle factors. By integrating this data, Arivale delivers tailored recommendations and personalized coaching to empower individuals in making informed decisions about their wellness. This comprehensive approach not only aids members in understanding their unique health profiles but also contributes to a growing dataset that supports medical research aimed at enhancing health outcomes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.